Published in Cancer Gene Ther on November 18, 2016
Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy. Transl Cancer Res (2017) 0.75
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Retracted Spontaneous human adult stem cell transformation. Cancer Res (2005) 4.95
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med (2010) 2.86
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood (2002) 2.43
Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med (2004) 2.35
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res (2005) 1.95
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev (2010) 1.78
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol (2000) 1.68
Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation (2006) 1.29
Electroporation and DNA-dependent cell death in murine macrophages. Immunol Cell Biol (1993) 1.28
Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer (2013) 1.15
The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology (2011) 1.08
Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res (2015) 1.08
Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release (2010) 1.06
Cancer electrogene therapy with interleukin-12. Curr Gene Ther (2010) 1.06
Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res (2013) 1.04
Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology (2002) 1.04
Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur J Immunol (2006) 0.99
Cancer gene therapy: challenges and opportunities. Anticancer Res (2004) 0.98
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget (2014) 0.92
A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop (2016) 0.92
Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol (1993) 0.90
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol (2015) 0.89
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther (2014) 0.87
Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J Stem Cells (2016) 0.86
Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. J Gene Med (2011) 0.86
Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev (2007) 0.86
DNA induces apoptosis in electroporated human promonocytic cell line U937. Biochem Biophys Res Commun (2000) 0.85
Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas. Cancer Gene Ther (2013) 0.84
Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release (2014) 0.83
Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells. Mol Ther Nucleic Acids (2016) 0.82
Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med (2013) 0.81
Cells as delivery vehicles for cancer therapeutics. Ther Deliv (2014) 0.81
A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses. J Leukoc Biol (2002) 0.80
Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology (2013) 0.78
Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases. Int Immunopharmacol (2015) 0.77
Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget (2016) 0.76
Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences. Int J Clin Exp Pathol (2014) 0.76